Overview

Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density

Status:
Not yet recruiting

Trial end date:
2023-11-15

Target enrollment:

Participant gender:

Summary

This is a randomized study to determine the effects of monthly romosozumab for one year or one-time zoledronic acid on bone mineral density (BMD) and biochemical markers of bone formation and resorption, in patients with spinal cord injury (SCI) and low BMD.

Phase:

Phase 4

Details

Lead Sponsor:

Sheba Medical Center

Treatments:

Zoledronic Acid